A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma

Evens, Andrew M.; Carson, Kenneth R.; Kolesar, Jill; Nabhan, Chadi; Helenowski, Irene; Islam, Nahida; Jovanovic, Borko; Barr, Paul M.; Caimi, Paolo; Gregory, Stephanie A.; Li, Gordon

doi:10.1093/annonc/mdt414

Cited by 47 publications

(38 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our cohort, the male to female ratio was 3:1, similar to that in children patients [31]. Also, similar with previous reports [32,8], most patients in our study had advanced stages and HR factors. Previous studies have confirmed the excellent efficacy of intensive treatment strategies in this highly aggressive lymphoma, and CODOX-M/IVAC regimen could produce a CR rate of about 90 % in adult patients [6,30].…”

Section: Discussionsupporting

confidence: 91%

Peripheral blood lymphocyte to monocyte ratio identifies high-risk adult patients with sporadic Burkitt lymphoma

Wang

Xia

et al. 2015

Ann Hematol

View full text Add to dashboard Cite

Adult sporadic Burkitt lymphoma (BL) is a rare subtype of lymphoma. In this retrospective study, we investigated the prognostic value of pretreatment lymphocyte to monocyte ratio (LMR) in a cohort of 62 patients. Using LMR <2.6 as the optimal cutoff point, 24 patients (38.7 %) had LMR <2.6. The complete response rates in high-LMR group and low-LMR group were 90.9 and 65.0 %, respectively (P = 0.019). At a median follow-up time of 41 months, the 3-year progression-free survival (PFS) rate and overall survival (OS) rates were 76 and 80 %, respectively. In a multivariate Cox regression model, it was found that the presence of bone marrow infiltration and low LMR were independently adverse prognostic factors for both PFS and OS. In the whole group, the addition of rituximab to treatment did not benefit patients significantly in PFS and OS. In subgroup analysis, in patients with high LMR, addition of rituximab can significantly improve survival outcomes (P = 0.046). In conclusion, we firstly found that low LMR (<2.60) was an independently adverse prognostic factor in adult patients with sporadic BL. Intensive chemotherapy could cure the majority of patients in our study, and the pretreatment LMR might predict the value of rituximab in this age population.

show abstract

Section: Discussionsupporting

confidence: 91%

Peripheral blood lymphocyte to monocyte ratio identifies high-risk adult patients with sporadic Burkitt lymphoma

Wang

Xia

et al. 2015

Ann Hematol

View full text Add to dashboard Cite

show abstract

“…Studies by Davis et al, Gordan et al and Jager et al suggested that bulky disease at baseline reduces plasma Rituximab concentrations, hence affecting the pharmacokinetic parameters [17][18][19]. But, a recent study in Burkitt's lymphoma suggested no such correlation [20]. We had a significant proportion of subjects with bulky disease (76.3 %), and no influence of bulky disease on pharmacokinetic parameters was observed.…”

Section: Discussionmentioning

confidence: 53%

Population pharmacokinetics of Reditux™, a biosimilar Rituximab, in diffuse large B-cell lymphoma

Gota

Karanam

Rath

et al. 2016

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

show abstract

“…Several groups have further modified this regimen with the addition of the anti-CD20 monoclonal antibody rituximab, demonstrating superior outcomes compared with historical controls [23][24][25]. Based upon these findings and extrapolating from studies in other histologies of lymphoma, rituximab should be routinely incorporated in the treatment algorithms of Burkitt lymphoma.…”

Section: Therapeutic Frontline Treatmentmentioning

confidence: 99%

Treating Burkitt Lymphoma in Adults

Casulo

Friedberg

2015

Curr Hematol Malig Rep

View full text Add to dashboard Cite

Burkitt lymphoma is an uncommon form of aggressive lymphoma affecting approximately 1200 patients per year in the USA. It is characterized by a translocation involving the MYC oncogene. Three subtypes of Burkitt lymphoma are recognized: the endemic form, occurring primarily in Africa and associated with the Epstein-Barr virus (EBV); the sporadic form, representing less than 3 % of all non-Hodgkin lymphomas (NHL); and the immunodeficiency-associated form, occurring primarily in HIV-infected patients. Burkitt lymphoma appears histologically with a diffuse pattern of intermediate-sized monomorphic B cells, multiple nucleoli, a very high proliferative rate, and frequent mitotic figures. Recent advances in transcriptional profiling have improved the current molecular understanding of Burkitt lymphoma and have better characterized its mutational landscape. Most Burkitt lymphoma patients are cured with intensive treatment; however, prognosis is poor in elderly patients and those with relapsed disease.

show abstract

A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma

Cited by 47 publications

References 18 publications

Peripheral blood lymphocyte to monocyte ratio identifies high-risk adult patients with sporadic Burkitt lymphoma

Peripheral blood lymphocyte to monocyte ratio identifies high-risk adult patients with sporadic Burkitt lymphoma

Population pharmacokinetics of Reditux™, a biosimilar Rituximab, in diffuse large B-cell lymphoma

Treating Burkitt Lymphoma in Adults

Contact Info

Product

Resources

About